As medical researchers and clinicians, we are concerned about the proposed reductions in funding for the U.S. National ...

Journal of Nuclear Medicine May 2025, jnumed.124.268938; DOI: https://doi.org/10.2967/jnumed.124.268938 ...

Our purpose was to evaluate the performance of the Biograph Vision Quadra PET/CT system. This new system is based on the Biograph Vision 600, using the same silicon photomultiplier–based detectors ...

Journal of Nuclear Medicine June 2025, jnumed.125.269655; DOI: https://doi.org/10.2967/jnumed.125.269655 ...

Personalization of treatment response through the use of on-treatment biomarkers is the future of theranostics and marks a key advantage of theranostics treatments over other systemic cancer therapies ...

Journal of Nuclear Medicine February 2025, jnumed.124.268967; DOI: https://doi.org/10.2967/jnumed.124.268967 Cancer therapy has advanced with molecularly targeted ...

Journal of Nuclear Medicine April 2025, jnumed.124.269361; DOI: https://doi.org/10.2967/jnumed.124.269361 ...

The field of nuclear medicine is going through a renaissance with significant investment by a biotechnology and pharmaceutical industry finally recognizing the benefits of the theranostic paradigm.

Single-domain antibody (sdAb) is among the most promising vectors for developing molecular imaging tracers. Several sdAb tracers targeting human epidermal growth factor receptor 2 or programmed death ...

The study of the human phenome is essential for understanding the complexities of wellness and disease and their transitions, with molecular imaging being a vital tool in this exploration. Molecular ...

EDA-FN is abundant in BC, with high EDA-FN expression associated with poor overall survival (15). Hormone receptor- and human epidermal growth factor receptor 2–negative BCs, collectively known as ...